Estimated read time: 2-3 minutes
HAEGENDORF, Switzerland--(BUSINESS WIRE)--Mar 5, 2014--Sensile Medical AG has completed the usability study for the semi-disposable patch pump that is developed for scPharmaceuticals LLC’s novel subcutaneous furosemide therapy.
Sensile Medical's Patch Pump for scFurosemide (Photo: Business Wire)
In the study health care professionals (HCPs) from seven hospitals in the United States and The Netherlands responded to questions about the subcutaneous application of furosemide ( scFurosemide ® ) in the treatment of heart failure and the handling of Sensile Medical’s new patch pump. The HCPs identified a broad range of clinical situations where scFurosemide treatment may improve both, the care process as well as patients’ outcomes.
The opportunity to treat patients with early stages of decompensation outside the emergency room or hospital emerged as the main advantage of this new scFurosemide treatment option over the current intravenous administration. The study participants expressed a strong interest in the use of the scFurosemide patch pump to better and more cost-effectively manage patients with heart failure.
“Using these devices with scFurosemide ® patients will be able to initiate effective treatment earlier when symptoms deteriorate.” said Rudolf Sidler, PhD, Product Manager at Sensile Medical. “In many cases this may prevent a visit to the emergency room or need for in-patient stay.“
“We are very pleased with the results of the study. They confirmed that we are on the right track with this unique combination product.” said Pieter Muntendam, MD, President and CEO of scPharmaceuticals. “Sensile’s precise micro pump technology enables a new generation of cost-effective devices previously not possible.”
Sensile Medical and scPharmaceuticals entered into a strategic partnership and supply agreement in the first quarter of 2013. The successful completion of this development milestone paves the way for the company’s first regulatory filings in 2015.
About Sensile Medical
Sensile Medical AG is a leading company in the area of advanced micro pump technology developing a broad range of customer-specific delivery and dosing solutions. Due to Sensile's SenseCore technology the products are highly cost-efficient, accurate, and safe. They are increasingly used in medical, industrial, and consumer applications. Founded in 2004, Sensile Medical is located in Haegendorf, Switzerland. For further information consult www.sensile-medical.com.
Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20140305005036/en/
CONTACT: Sensile Medical AG
Lars G. Krinelke, MD, PhD
Head of Product Management
KEYWORD: EUROPE SWITZERLAND
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY HOSPITALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Sensile Medical AG
Copyright Business Wire 2014
PUB: 03/05/2014 04:00 AM/DISC: 03/05/2014 04:00 AM